BERLIN—The German biotech firm that has partnered with Pfizer Inc. to develop a coronavirus vaccine is confident it will be ready to seek regulatory approval by the end of the year, according to its chief executive.

Several hundred million doses could be produced even before approval, and over 1 billion by the end of 2021, BioNTech SE co-founder and CEO Dr. Ugur Sahin told The Wall Street Journal.

BioNTech,…

Read More